Premium
P2‐260: Cognitive assessment of mild cognitive impairment
Author(s) -
McGuinness Bernadette,
Johnston Janet,
Passmore Peter
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.968
Subject(s) - neurocognitive , audiology , verbal fluency test , trail making test , psychology , cambridge neuropsychological test automated battery , cognition , executive functions , sentence completion tests , episodic memory , neuropsychology , dementia , boston naming test , cognitive test , stroop effect , memory clinic , working memory , spatial memory , medicine , cognitive impairment , psychiatry , developmental psychology , disease
Background: Recent guidelines for mild cognitive impairment (MCI) have suggested domains other that memory should be tested including executive function, language, visuospatial skills and attention. The purpose of this study was to carry out a full neurocognitive assessment in patients diagnosed with MCI.Methods: Patients were recruited from the Belfast City Hospital memory clinic. Controls were also recruited. Both patients and controls were invited to undergo a neurocognitive test battery. This comprised tests for pre morbid IQ (NART), learning and episodicmemory (NYUparagraph 1&2; delayed match to sample and paired associate learning from CANTAB), executive function and attention (CLOX 1, Colour Trails 1&2, Stroop, Hayling Sentence Completion Test), language (COWAT verbal fluency test) and visuospatial function (Brixton Spatial Anticipation Test , CLOX2). Results: 139 patients with MCI and 98 controls were assessed. There was no significant difference between the MCI and control group in terms of age (t 1⁄4 -1.54, P 1⁄4 0.12), gender (c2 1⁄4 0.24, P 1⁄4 0.63), years of education (t 1⁄4 1.48, P 1⁄4 0.14), premorbid IQ (t 1⁄4 0.20, P 1⁄4 0.84) or function as measured by the Disability Assessment of Dementia (t 1⁄4 -0.50, P 1⁄4 0.62). There was a significant difference in MMSE (t 1⁄4 -9.04, P <0.01) and ACE (t 1⁄4 -2.22, P1⁄4 0.03) between theMCI and control group as was expected. Results of the neuropsychological tests are illustrated in Table 1.In order to differentiate cognitive domains we set a cut off for each test at 1.5 standard deviations below the control mean. An impaired result on at least one test in each cognitive domain was required to be considered impaired in the domain. MCI patients were then assigned to groups: amnestic single domain, amnestic multidomain, nonamnestic single domain and nonamnestic multidomain. 25 (18%) patients were classified as no problem, 13 (9.4%) amnestic single domain, 65 (46.8%) amnestic multidomain, 26 (18.7%) nonamnestic single domain and 10 (7.2%) nonamnestic multidomain. Conclusions: We have demonstrated significant impairments in cognitive domains other than memory in this cohort of MCI patients. Most patients had deficits in multiple domains. This illustrates the importance of carrying out a full neurocognitive assessment on patients presenting to a memory clinic. P2-261 COGNITIVE TRAJECTORIES ASSOCIATEDWITH BETA-AMYLOID DEPOSITION IN THE NONDEMENTED OLDEST-OLD Beth Snitz, Lisa Weissfeld, Oscar Lopez, Lewis Kuller, Judith Saxton, Dilrukshika Singhabahu, William Klunk, Julie Price, Chester Mathis, Ann Cohen, Steven DeKosky, University of Pittsburgh, Pittsburgh, Pennsylvania, United States; 2 University of Virginia School of Medicine, Charlottesville, Virginia, United States.